Cardiovascular disease is the major cause of premature mortality in Western societies [1] . The major underlying process is atherosclerosis leading to the formation of unstable plaques followed by thrombotic occlusion of the coronary arteries, myocardial ischemia, heart failure and death [2] . Recently it has been definitively demonstrated that in human atherosclerosis the pathological process commences with the deposition of lipid in areas of diffuse intimal thickenings [3, 4] 
lipoprotein (LDL) bind to negatively charged glycosaminoglycan (GAG) chains on proteoglycans. It has been speculated that growth factor-induced changes in the GAG chains bestow a greater attraction for lipid and is a crucial step for the atherosclerotic cascade that follows
.
Platelet-derived growth factor (PDGF) stimulates the production and increases the size of proteoglycans, with the latter response due to elongation of GAG chains [9, 10] . PDGF stimulates the expression of mRNA for proteoglycan core proteins, specifically, versican [10] and PDGF also increases the 6:4 position sulphation ratio of disaccharides [9] . Imatinib, is a small molecule tyrosine kinase inhibitor used for the treatment of human chronic myeloid leukaemia [11] . Imatinib is a 2-phenylaminopyrimidine [12, 13] and has potent activity against BCR-ABL, the transforming tyrosine kinase found in CML cells [12] . [14] and FMS [15] .
In addition to ABL, imatinib has been reported to inhibit PDGF receptor (PDGFR)-␣, PDGFR-␤ and KIT

We investigated the effects of imatinib on PDGF mediated proteoglycan size and fine structure and resultant proteoglycan/LDL binding in an in vitro cell culture model and further investigated its ability to reduce lipid deposition ex vivo and in vivo in two mouse models.
Materials and methods
Preparation of human vSMC cultures
Human vSMCs were isolated from otherwise discarded segments of the internal mammary artery from patients undergoing cardiac surgery at the Alfred Hospital (Melbourne, Australia), as previously described [16] .
Acquisition and use of tissue conformed to the principles of the Human Ethics Committee of the Alfred Hospital.
Quantitation of radiolabel incorporation into proteoglycans
Quiescent cells were treated in 5 24 hrs. Secreted proteoglycans were harvested and radiolabel incorporation into proteoglycans quantitated using the CPC precipitation assay [17] .
Chemical cleavage of glycosaminoglycan chains
Quiescent cells were treated with imatinib (1 mol/l) in 0. 5 [18] . To chemically cleave the GAG chains through a ␤-elimination reaction, pelleted proteoglycans were treated with sodium borohydride (1 M) 
Synthesis of xyloside initiated GAG chains
Quiescent human vSMCs were treated in 0. 5 [18] .
Size analysis of proteoglycan/GAG length by SDS-PAGE and size exclusion chromatography
Proteoglycans, cleaved GAG chains and xyloside associated GAG chains were sized by SDS-PAGE as described previously [17] . Cleaved GAG chains and xyloside associated GAG chains were sized on sepharose CL-6B columns eluted in guanidine buffer as described previously [6] 
Analysis of disaccharides by fluorophore assisted carbohydrate electrophoresis (FACE)
To analyse the disaccharide composition of GAG chains the FACE method was used as described by Calabro [20] . Human vSMCs were seeded into 75 cm 2 [6] . 
Western blotting
Evaluation of lipid lesion formation
The aorta was used for en face evaluation of atherosclerotic lesion area. Aortae were carefully cleaned of adventitia and separated from the heart under a dissecting microscope, split longitudinally and pinned. Lipid deposition in the aorta was visualized as described previously [22] . Sudan IVpositive lesion areas were quantified from digitized images using Optimas image analysis software. All analyses were made in masked fashion by the two investigators. The extent of lipid lesion formation was expressed as the percentage of total aortic surface area. 3 H-glucosamine incorporation into GAG chains of secreted proteoglycans by 43%, P Ͻ 0.01 (Fig. 1C) . PDGF stimulated a 77% increase, P Ͻ 0.01, in 3 H-glucosamine incorporation and imatinib treatment decreased this PDGF mediated increase in by 64%, P Ͻ 0.01 (Fig. 1C) . The decrease in radiolabel incorporation from the basal state is most probably due to inhibition of the autocrine action of endogenously produced PDGF [26] . PDGF stimulated proteoglycan core protein synthesis and imatinib treatment decreased 35 S-met/cys incorporation by 32%, P Ͻ 0.01 (Fig. 1D) . Fig. 2A, lane 7 versus 8) . A representative size exclusion analysis is shown (Fig. 2B) Table 1 ). (Fig. 2A, lanes 1-4; Fig. 2C, lanes 1-4) . Table 1 ). Thus imatinib inhibits the biochemical process of GAG elongation which is activated by PDGF.
Measurement of arterial lipid accumulation
Results
Imatinib inhibits proteoglycan synthesis and GAG elongation
Imatinib treatment of human vSMC in the presence of PDGF dose dependently decreased 35 S-SO4 incorporation into secreted proteoglycans with a maximal inhibition of 66% at 10 mol/l imatinib, with an IC50 value of approximately 700 nmol/l (Fig. 1A). The imatinib resistant component of proteoglycan synthesis may represent a basal or endogenous component not amenable to pharmacological inhibition. The electrophoretic mobility of complete proteoglycans isolated from human vSMC after treatment with imatinib, was dose dependently increased relative to PDGF treatment alone (Fig. 1B). Under basal conditions imatinib treatment decreased
SDS-PAGE analysis showed the action of PDGF to decrease the electrophoretic mobility and imatinib treatment to increase mobility of the cleaved GAG chains (
Synthesis of GAG chains on a xyloside primer is a technique that allows evaluation of GAG synthesis which is independent of proteoglycan core protein [27]. SDS-PAGE analysis showed identical results to that seen with intact proteoglycans indicating that the action of imatinib on intact proteoglycans was identical to that of xyloside GAGs
Treatment of human vSMC with PDGF resulted in xylosideinitiated GAG chains with decreased electrophoretic mobility
Imatinib decreases 6:4 position sulphation ratio of disaccharide units
Stimulation of human vSMC with PDGF increased the mean 6:4 position sulphation ratio assessed by FACE from 1.0 to 2.0, P Ͻ 0.01 (Fig. 3A) . This is consistent with previous reports of increases in the 6:4 position sulphation ratio upon stimulation with PDGF [9, 28] . Under basal conditions, imatinib decreased the mean 6:4 sulphation ratio from 1.0 to 0.6, P Ͻ 0.01 (Fig. 3A) . Imatinib treatment in the presence of PDGF decreased the mean 6:4 sulphation ratio from 2.0 to 1.4, P Ͻ 0.01 (Fig. 3A) .
Imatinib decreases proteoglycan/LDL binding
To assess the LDL binding properties of proteoglycans isolated from imatinib treated human vSMC the gel mobility shift assay was used [29] . The half maximal saturation value for control proteoglycans was approximately 0.01 mg/ml LDL compared to 0.04 mg/ml LDL for proteoglycans from imatinib treated cells (Fig. 3B) (Fig. 4A) . (Fig. 4B) .
The effect of imatinib to inhibit lipid deposition was most effective in the aortic arch region (Fig. 4A). Clearly imatinib reduced lipid deposition even though plasma lipid levels were not reduced. To determine if decreased LDL retention was the mechanism accounting for the decreased atherosclerosis observed, LDL retention was quantified in carotid arteries from mice that had received angiotensin II (used to increase vascular matrix content [24]) with (n ϭ 3) or without (n ϭ 4) imatinib in the diet for 28 days. The carotid arteries were alternately perfused with fluorescent LDL or non-fluorescent buffer, thus each artery serves as its own control. Quantitative fluorescence microscopy demonstrated
Effect of imatinib on the PDGF receptor phosphorylation in human vascular smooth muscle cells
We examined PDGFR phosphorylation following exposure of human vSMCs to PDGF. We performed Western blot analysis of the growth factor PDGF-mediated phosphorylation of the autophosphorylation activation site of the PDGFR (Tyr 857). PDGF markedly increased phosphotyrosine 857 levels on PDGFR reaching a peak around 30 min. (data not shown). To investigate the action of imatinib on PDGFR signalling we treated cells with imatinib (1 mol/l) in the absence and presence of PDGF (50 ng/ml, 20 min.) and demonstrated that imatinib almost completely abolished the PDGF-mediated phosphorylation of tyrosine 857 of PDGFR
Discussion
Proteoglycans play a crucial role in the binding and retention of LDL in early human atherosclerosis [3, 4] . [18] . Proteoglycans synthesized in the presence of fenofibrate [6] and amlodipine [35] [9] . The possible mechanism by which imatinib decreases 6 position sulphation may be inhibition of the activity or expression of a specific 6-sulfotransferase(s). 
